|[January 07, 2013]
EPIRUS Biopharmaceuticals, Inc. Announces Positive Phase 1 Data for BOW-015
BOSTON --(Business Wire)--
EPIRUS Biopharmaceuticals, Inc. ("EPIRUS"), formerly known as fourteen22
Inc, announced that its lead asset, BOW-015, achieved bioequivalence to
Remicade® in a single dose comparator trial.
In February 2012, the United Kingdom's MHRA (Medicines and Healthcare
Regulatory Agency) approved a single center, double blind, randomized
parallel group trial in 84 healthy male volunteers each of whom received
a 5 mg/kg single infusion of BOW-015 or Remicade®.
At the conclusion of the trial, BOW-015 met both the primary objectives
of bioequivalence in Cmax, AUC(0-t) and AUC(0-8), as well as the
secondary objectives of safety, tolerability and immunogenicity.
"The data from this Phase 1 study are encouraging and support the
bioequivalence of BOW-015 with Remicade. Biosimilars, when developed
with the proper rigor, will offer patients around the world similarly
effective biological therapies that should be less costly than those
currently available. I look forward to seeing data from the ongoing
Phase 3 trial," commented Jonathan Kay, MD, Professor of Medicine,
University of Massachusetts Medical School, and Director of Clinical
Research, Division of Rheumatology, UMass Memorial Medical Center,
EPIRUS is currently conducting a registrational Phase 3 program for
BOW-015 with initial data expected in late 2013.
EPIRUS was financed in early 2011 by 5AM Ventures, Montreux Equity
Partners and TPG Biotech. Following a restructuring in 2012, EPIRUS has
expanded its focus to centrally develop a broad pipeline of biosimilar
monoclonal antibodies, optimised for use within its SCALE™ disposable
manufacturing system, and designed to be deployed in an "In Market, For
Market" ™ manufacturing configuration. This innovative platform is
designed to enable localized manufacturing in key emerging economies
where EPIRUS is developing prtnerships combining public and private
sector financial support and expertise.
EPIRUS President and Chief Executive Officer, Amit Munshi commented, "We
are pleased with this initial data and are excited to continue working
with our In Market partners globally to continue building out our
product pipeline and regional manufacturing model."
About EPIRUS Biopharmaceuticals
EPIRUS is focusing on the central development of a broad pipeline of
biosimilar monoclonal antibodies and therapeutic proteins, optimized for
use within the SCALE™ disposable manufacturing system, and designed to
be deployed in an "In Market, For Market" ™ manufacturing configuration.
SCALE is a modular state-of-the-art manufacturing process utilizing the
latest in disposable technology. It is ideally suited for use as a
localized In Market, For Market manufacturing solution designed to
provide speed to market, low capital cost, campaign flexibility and
utilization rates which can be tailored to local and or regional needs.
This innovative product platform aims to enable localized manufacturing
in emerging economies where EPIRUS is developing partnerships combining
public and private sector financial support and expertise. EPIRUS is
focusing on a range of emerging markets, including, Brazil, Turkey,
Russia, MENA, and the ASEAN markets.
EPIRUS envisions the creation of unprecedented patient access to
biosimilar therapeutics through efficient global development and local
production of these important medicines.
About 5AM Ventures
5AM Ventures is an early-stage venture capital firm focused on building
next-generation life science companies. Founded in 2002, 5AM Ventures
has over $435 million under management and is actively investing 5AM
Ventures III, L.P., a $220 million fund. The firm has offices in Menlo
Park, CA (News - Alert) and Waltham, MA. 5AM is directly involved in company strategy,
management recruiting, business development and fundraising and often
takes on short-term operating roles. For more information visit www.5amventures.com.
About Montreux Equity Partners
Montreux Equity Partners (MEP) is a private investment firm dedicated to
building the leading healthcare companies of tomorrow. Located in
Silicon Valley and San Francisco, MEP currently invests out of its
fourth fund, a $250 million vehicle. MEP focuses on companies that
pursue compelling commercial growth opportunities. MEP's portfolio has a
significant global presence, including operations in the U.S., Europe,
Latin America, and Asia. For more information visit www.mepvc.com.
About TPG Biotech
TPG Biotech is part of the growth equity and venture investment platform
of TPG, the global private investment firm. With more than $1.2 billion
under management, TPG Biotech targets investments in pharmaceutical
discovery and development, medical technology, diagnostics, healthcare
and pharmaceutical services, life sciences, as well as industrial
applications of biotechnology. For more information visit www.tpgbiotech.com.
[ Back To Technology News's Homepage ]